4.7 Article

Krill Oil Treatment Increases Distinct PUFAs and Oxylipins in Adipose Tissue and Liver and Attenuates Obesity-Associated Inflammation via Direct and Indirect Mechanisms

Journal

NUTRIENTS
Volume 13, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/nu13082836

Keywords

krill oil; polyunsaturated fatty acids (PUFAs); obesity; inflammation; oxylipins; adipogenesis

Funding

  1. PPP Allowance by Health-Holland, Top Sector Life Sciences and Health
  2. TNO program Biomedical Health
  3. ZonMW (The Enabling Technologies Hotels program) [435005007]

Ask authors/readers for more resources

Long-term treatment with krill oil leads to increased concentrations of anti-inflammatory compounds in white adipose tissue and liver, resulting in beneficial effects on metabolism and inflammation at the tissue level.
The development of obesity is characterized by the metabolic overload of tissues and subsequent organ inflammation. The health effects of krill oil (KrO) on obesity-associated inflammation remain largely elusive, because long-term treatments with KrO have not been performed to date. Therefore, we examined the putative health effects of 28 weeks of 3% (w/w) KrO supplementation to an obesogenic diet (HFD) with fat derived mostly from lard. The HFD with KrO was compared to an HFD control group to evaluate the effects on fatty acid composition and associated inflammation in epididymal white adipose tissue (eWAT) and the liver during obesity development. KrO treatment increased the concentrations of EPA and DHA and associated oxylipins, including 18-HEPE, RvE(2) and 14-HDHA in eWAT and the liver. Simultaneously, KrO decreased arachidonic acid concentrations and arachidonic-acid-derived oxylipins (e.g., HETEs, PGD(2), PGE(2), PGF(2)alpha, TXB2). In eWAT, KrO activated regulators of adipogenesis (e.g., PPAR gamma, CEBP alpha, KLF15, STAT5A), induced a shift towards smaller adipocytes and increased the total adipocyte numbers indicative for hyperplasia. KrO reduced crown-like structures in eWAT, and suppressed HFD-stimulated inflammatory pathways including TNF alpha and CCL2/MCP-1 signaling. The observed eWAT changes were accompanied by reduced plasma leptin and increased plasma adiponectin levels over time, and improved insulin resistance (HOMA-IR). In the liver, KrO suppressed inflammatory signaling pathways, including those controlled by IL-1 beta and M-CSF, without affecting liver histology. Furthermore, KrO deactivated hepatic REL-A/p65-NF-kappa B signaling, consistent with increased PPAR alpha protein expression and a trend towards an increase in IkB alpha. In conclusion, long-term KrO treatment increased several anti-inflammatory PUFAs and oxylipins in WAT and the liver. These changes were accompanied by beneficial effects on general metabolism and inflammatory tone at the tissue level. The stimulation of adipogenesis by KrO allows for safe fat storage and may, together with more direct PPAR-mediated anti-inflammatory mechanisms, attenuate inflammation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available